# Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator

Study · id `cardio:ct-nct06964464` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06964464](<https://clinicaltrials.gov/study/NCT06964464>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06964464

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems; Heart failure; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2000 participants.

## Technical summary

Registry record NCT06964464. Randomized; no masking; primary purpose treatment. Start 2025-08-17 (actual); primary completion 2031-06-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2000 participants (planned count; ClinicalTrials.gov record NCT06964464, source copy `cardio:ctgov-nct06964464-2025-09-18`, retrieved 2026-10-26)
- Started: 2025-08-17 (actual) (ClinicalTrials.gov record NCT06964464, source copy `cardio:ctgov-nct06964464-2025-09-18`, retrieved 2026-10-26)
- Primary completion: 2031-06-01 (anticipated) (ClinicalTrials.gov record NCT06964464, source copy `cardio:ctgov-nct06964464-2025-09-18`, retrieved 2026-10-26)
- Completion: 2031-07-01 (anticipated) (ClinicalTrials.gov record NCT06964464, source copy `cardio:ctgov-nct06964464-2025-09-18`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT06964464, source copy `cardio:ctgov-nct06964464-2025-09-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06964464-2025-09-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator
- Acronym: CARVTOP-ICD
- Condition: Heart Failure With Reduced Ejection Fraction (HFrEF)
- Condition: Sudden Cardiac Death
- Condition: Ventricular Arrhythmia
- Condition: Implantable Cardioverter Defibrillator (ICD)
- Condition: Beta-blocker Therapy
- Condition: Cardiomyopathy
- Intervention (Drug): Metoprolol Succinate
- Intervention (Drug): Carvedilol
- Lead sponsor: University of Rochester
- Lead sponsor class: OTHER
- Collaborator: Patient-Centered Outcomes Research Institute
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition term reads as this condition, and the trial is coded with its broader condition: Heart failure with reduced ejection fraction (HFrEF) (`cardio:hfref`)
- Registry condition terms include this condition: Sudden cardiac arrest (`cardio:sudden-cardiac-arrest`)
- Registry intervention name matches this record: Carvedilol (`cardio:carvedilol`)
- Registry intervention is a member of this class by a sourced record link: Beta-blockers (drug class) (`cardio:beta-blockers`)
- Registry lists this organization as the lead sponsor: University of Rochester (`cardio:org-university-of-rochester`)
- Registry lists this organization as a collaborator: Patient-Centered Outcomes Research Institute (`cardio:org-patient-centered-outcomes-research-institute`)

## Provenance

Content hash: ac4da2e09fe8e73bf9715690c3976697a3a1c50d7e9c0701ad8b8207d02eb14a
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
